Clinical trials: pMMR/MSS Locally Advanced Rectal Cancer
Rectal Cancer
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
This study aims to evaluate the effectiveness and safety of combining moderately hypofractionated radiotherapy with chemotherapy and anti-PD-1 antibodies as a neoadjuvant treatment for high-risk locally advanced rectal cancer.
- Trial name
- iMHRT-LARC (NCT06599827)
- Testing
- moderately hypofractionated radiotherapy, chemotherapy, immunotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Rectal Cancer
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
The goal of this clinical trial is to learn if node-sparing modified short-course radiotherapy combined with tislelizumab and CAPOX works to treat pMMR/MSS locally advanced mid-to-low rectal cancer.
- Trial name
- mRCATS (NCT07900061)
- Testing
- node-sparing modified short-course radiotherapy, standard short-course radiotherapy
- Volunteers
- 210 people
- Sponsor
- Sir Run Run Shaw Hospital
Rectal Cancer Patients
Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer
This study is for adults with locally advanced rectal cancer that has not spread to distant organs, and is classified as pMMR or MSS (which means it typically does not respond well to immunotherapy alone).
- Trial name
- NCT07521605
- Testing
- Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Cancer Patients
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
This study is a multicenter, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of short-term radiotherapy combined with Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as…
- Trial name
- NCT06911684
- Testing
- lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody
The investigators conduct a single-arm, single-center, prospective clinical study enrolling patients diagnoses with pMMR / MSS type middle and low locally advanced rectal cancer who had not received systemic anti-tumor therapy to…
- Trial name
- PMMR/MSS (NCT06014944)
- Testing
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Locally Advanced Rectal Cancer
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
In pMMR/MSS locally advanced rectal cancer, can the innovative "chemo-immunotherapy induction + LCRT + chemo-immunotherapy consolidation" approach significantly improve the complete response rate and create opportunities for…
- Trial name
- NCT07527026
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Chinese PLA General Hospital